Patent · US Active

Method for diagnosing multiple sclerosis

US8216791B2 · kind B2 · utility

0Cited by

4References

6Claims

0Family size

Assignee

Glycominds, LLC · IL

Inventors

Nir Dotan · Shoham, IL
Avinoam Dukler · Lod, IL

Key dates

Filing date	Sep 9, 2009
Grant date	Jul 10, 2012
Priority date	—
Expiry date	Jun 3, 2030

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/285
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Disclosed is a method for diagnosing and prognosing multiple sclerosis and more particularly to a method for diagnosing and prognosing multiple sclerosis by measuring levels of antibodies. The levels of IgM-type anti-Glc(α1,2)Glc(α) or Glc(α1,3)Glc(α) or Glc(α1,6)Glc(α) antibodies in serum act as diagnostic markers for MS disease and as prognostic biomarkers for the conversion of CIS patients suggestive of MS to clinically definite MS (CDMS) within 24 months.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.